Literature DB >> 21131101

Progress in infection prevention and control in Italy: a nationwide survey.

M L Moro1, M Marchi, R Buttazzi, S Nascetti.   

Abstract

A national survey was conducted to describe the coverage and characteristics of infection prevention and control (IC) programmes in Italy and to evaluate progress during recent years. All regions, with one small exception, participated and the response rate was 88%. Nearly all 278 respondent public health trusts reported having an IC committee, 80% of the 615 respondent hospitals to have instituted an IC team, and 79% to have an IC nurse. However, when the presence of truly operating IC bodies was considered, the pattern was different: only 27% of IC teams met at least monthly, and variation by region was extremely large [coefficient of variation (CV): 1.06]. The IC programme characteristics with the greatest variation by region included: availability of qualified nurses and IC doctors (CV: 1.55 and 1.39 respectively); integration of IC activities and clinical risk management (CV: 1.05); IC programmes also involving community services (CV: 0.98); training of personnel at induction (CV: 0.82); and availability of written policies for the control of multidrug-resistant organisms (CV: 1.08). A relevant and statistically significant North-South gradient showed Southern Regions averaging 23 points less than Northern Regions on the IC score. Compared with a similar survey conducted in 2000, the distribution of several activities by region had improved significantly. Despite the noteworthy improvement observed over time, the situation in Italy is still unsatisfactory, due to significant variation in the development of IC organisations and initiatives by region and by type of hospital.
Copyright © 2010 The Hospital Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21131101     DOI: 10.1016/j.jhin.2010.08.009

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  7 in total

1.  A survey of methicillin-resistant Staphylococcus aureus control strategies in Italy.

Authors:  A Pan; E Bombana; G Tura; C Curti; S Lorenzotti; P Mondello; A Patroni; E Tacconelli; V Rigobello; L Signorini; M Vizio; A Goglio
Journal:  Infection       Date:  2013-04-01       Impact factor: 3.553

2.  Appropriate use of antimicrobial prophylaxis: an observational study in 21 surgical wards.

Authors:  Marco Testa; Michela Stillo; Sebastian Giacomelli; Silvia Scoffone; Pier Angelo Argentero; Enzo Carlo Farina; Carla Maria Zotti
Journal:  BMC Surg       Date:  2015-05-14       Impact factor: 2.102

3.  Assessment of the Activity of Tigecycline against Gram-Positive and Gram-Negative Organisms Collected from Italy between 2012 and 2014, as Part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.).

Authors:  Stefania Stefani; Michael J Dowzicky
Journal:  Pharmaceuticals (Basel)       Date:  2016-11-26

4.  Determinants of success and sustainability of the WHO multimodal hand hygiene promotion campaign, Italy, 2007-2008 and 2014.

Authors:  Maria Luisa Moro; Filomena Morsillo; Simona Nascetti; Mita Parenti; Benedetta Allegranzi; Maria Grazia Pompa; Didier Pittet
Journal:  Euro Surveill       Date:  2017-06-08

5.  Assessing hand hygiene compliance among healthcare workers in six Intensive Care Units.

Authors:  M Musu; A Lai; N M Mereu; M Galletta; M Campagna; M Tidore; M F Piazza; L Spada; M V Massidda; S Colombo; P Mura; R C Coppola
Journal:  J Prev Med Hyg       Date:  2017-09

6.  Surveillance of healthcare-associated infections in Piemonte, Italy: results from a second regional prevalence study.

Authors:  Lorena Charrier; Pier Angelo Argentero; Enzo C Farina; Roberto Serra; Francesco Mana; Carla M Zotti
Journal:  BMC Public Health       Date:  2014-06-05       Impact factor: 3.295

7.  Data quality assessment and subsampling strategies to correct distributional bias in prevalence studies.

Authors:  A D'Ambrosio; J Garlasco; F Quattrocolo; C Vicentini; C M Zotti
Journal:  BMC Med Res Methodol       Date:  2021-04-30       Impact factor: 4.615

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.